#ovariancancer #ovariancancerresearch #ovariancancersurvivor #ovariancancersurvivors #ovariancancerawareness #gyncsm #sgomtg

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor, according to research presented at #SGOMtg by Dr Hyun-Woong Cho of Korea University. #SGO2025 #gyncsm shorturl.at/b0R0n

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #SGO25 #ovca #oncology www.onclive.com/view/ocular-...

Pembro + chemo followed by pembro-olaparib maintenance ± bevacizumab improved PFS vs chemo ± bevacizumab in patients with advanced ovarian cancer in the KEYLYNK-001 trial. Presented at #SGOMtg by Dr Matthew Powell of @washumedicine.bsky.social. #SGO2025 #gyncsm shorturl.at/k5Frm

Luveltamab tazevibulin demonstrated activity in a phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer. Data were presented at #SGOMtg by Jung-Yun Lee of Yonsei University College of Medicine. #SGO2025 #gyncsm shorturl.at/v1Vrz

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/pamipar...

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

Rina-S Generates Durable Responses in Advanced Platinum-Resistant Ovarian Cancer @danafarber.bsky.social #SGOMtg #SGO2025 #gyncsm
www.onclive.com/view/rina-s-...

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer #SGO2025 #SGOMtg #gyncsm

www.onclive.com/view/dostarl...

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
#SGO2025 #SGOMtg #gyncsm
www.onclive.com/view/real-wo...

Neoadjuvant nivolumab has demonstrated efficacy in patients with dMMR, surgically resectable endometrial cancer, according to data presented at #SGOMtg by Dr Yong Jae Lee of Yonsei University College of Medicine. #SGO2025 #gyncsm shorturl.at/rHZjS

Mirvetuximab soravtansine improved OS vs chemo in patients with FRα+, platinum-resistant ovarian cancer in the MIRASOL trial. Data were presented at #SGOMtg by Dr Toon Van Gorp of @uzleuven.bsky.social. #SGO2025 #gyncsm shorturl.at/n4n3o

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/metform...

#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Lindsay Kuroki, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8

Pembrolizumab Provides Long-Term Benefits in Cervical Cancer Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer in the KEYNOTE-A18 trial, presented at #SGOMtg by Dr Linda Duska of @uvahealth.bsky.social. #SGO2025 #gyncsm shorturl.at/shcSW

Antibody-Drug Conjugate Proves Active in Ovarian Cancer A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer.

DB-1305/BNT325 demonstrated durable activity in patients with previously treated ovarian cancer, according to data presented at #SGOMtg by Dr Maria Rubinstein of @mskcancercenter.bsky.social. #SGO2025 #gyncsm shorturl.at/tA2bw

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer #SGOMtg #SGO2025 #ovca

www.onclive.com/view/frontli...

CRT No Better Than RT as Adjuvant Therapy in Early Cervical Cancer Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

Adjuvant CRT does not improve outcomes vs adjuvant RT in intermediate-risk, early-stage cervical cancer, according to phase 3 data presented at #SGOMtg by Dr Sang Young Ryu of the Korea Cancer Center Hospital. #SGO2025 #gyncsm shorturl.at/cYuYj

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer #SGOMtg #SGO25 #gynsm #oncology www.onclive.com/view/puxitat...

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #ovca #gyncsm www.onclive.com/view/updated...

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer @pennmedicine.bsky.social #gyncsm #SGOMtg #SGO2025
www.onclive.com/view/cyclin-...

#ovariancancer #ovariancancerawarness #ovariancancerresearch #ovariancancersurvivor #gyncsm #sgomtg

#SGOmtg: @washumedicine.bsky.social gynecologic oncologist and surgeon Matthew A. Powell, MD, presents today. #SGOMtg #AM25IMPACT

Check out the conference details here: bit.ly/4ioTbE8

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer #SGOMtg #AM25IMPACT #SGO2025 #oncology #gyncsm
www.onclive.com/view/zimbere...

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm #oncology
www.onclive.com/view/afurese...

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 www.onclive.com/view/olapari...

We’re diving into our first full day of #SGO2025, starting with this morning's plenary session on maximizing therapeutic benefit through targeted strategies and predictive assays.

Want to share your expert take? Contact us to schedule an interview! #SGOMtg #gynsm

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer @uvahealth.bsky.social #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/pembrol...

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
#SGOMtg #AM25IMPACT #SGO2025
www.onclive.com/view/cadonil...

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer #SGOMtg #AM25IMPACT #SGO2025 #gyncsm www.onclive.com/view/nivolum...